Meaningful Use Guidance

Illuminating the Path Towards Compliance


The journey towards Meaningful Use compliance doesn't have to be difficult. EHRpath offers a multitude of solutions that addresses everything from workflow efficiency to regulatory measures and compliance. The result: minimized disruptions, avoidance of potential Medicare penalties and the ability to focus on your patients — all while maximizing government-supported monetary incentives.

Qualified practices that begin participating in the Meaningful Use incentive program in 2012 are eligible for the maximum payment of $44,000.1

Year 2012 2013 2014 2015 2016 Total
2012 $18,000 $12,000 $8,000 $4,000 $2,000 $44,000
2013 $15,000 $12,000 $8,000 $4,000 $39,000
2014 $12,000 $8,000 $4,000 $24,000

Miraca Life Sciences provides:

  • Meaningful Use and regulatory consultants to offer dedicated support to your practice
  • Detailed analysis to map out existing workflows and propose new ones
  • Consistent guidance on forthcoming regulatory concerns and compliance
  • Comprehensive documentation of EHR Policy and Procedure to ensure HIPAA compliance
  • Extensive Meaningful Use services in Assessment, Planning, Selection, Implementation, Evaluation and Development

Make things simpler. Employ our expertise towards becoming Meaningful Use compliant. Contact us at 855.EHR.PATH (347.7284) or by email at MeaningfulUse@MiracaLS.com.

1. Woodcock, EW. Sage Software Healthcare, LLC. Understanding the “Meaningful Use” regulations. 2010.

Choose Miraca for Your Patients


Learn more about Miraca's Anatomic Pathology services

Learn More »

We have been using Miraca for about 20 months, and they are outstanding. They have a daily conference with all of their Dermpaths across the country where they [collaborate on] tough cases.
— Joel Cohen, MD


READ MORE
Learn about Miraca's unmatched quality. We provide our clients with access to the highest quality AP services.

Recent News


April 18, 2017

Miraca Research News: Philips receives FDA clearance to market Philips IntelliSite Pathology Solution for primary diagnostic use in the US

Pathologists at Miraca Life Sciences contributed significantly in the development of a new product from Philips, the IntelliSite Pathology Solution. As one of four clinical study sites, Miraca Life Sciences participated in “one of the largest studies ever conducted to directly compare the use of digital pathology to optical microscopes.” At Miraca, participation in the Philips study was a project of Miraca […]

Continue reading


April 11, 2017

Ten Research Projects from Miraca Life Sciences Accepted for DDW Conference

IRVING, Texas, April 12, 2017 — Ten research projects from the GI pathologists at Miraca Life Sciences, the nation’s largest independent anatomic pathology lab, have been accepted for presentation at the Digestive Disease Week® conference (DDW), which will be held May 6–9 in Chicago. DDW is the world’s largest gathering of physicians, researchers and industry in the fields of gastroenterology, […]

Continue reading


March 27, 2017

Simponi® is Sixth Drug in InformTx™ Therapeutic Drug Monitoring Service from Miraca Life Sciences

IRVING, Texas, March 28, 2017 — Miraca Life Sciences, the largest U.S. independent anatomic pathology laboratory, continues to expand its InformTx™ therapeutic drug monitoring (TDM) capabilities, now testing for Simponi (golimumab) as well as patient-developed antibodies to Simponi. This is the first TDM assay available in the United States for Simponi. With this addition, Miraca Life Sciences now performs TDM […]

Continue reading


November 30, 2016

Stelara® Now Available for Therapeutic Drug Monitoring from Miraca Life Sciences

IRVING, Texas, December 1, 2016 — Miraca Life Sciences, the largest U.S. independent anatomic pathology lab, has expanded its InformTx™ therapeutic drug monitoring service for drugs that treat inflammatory bowel disease (IBD) with the addition of Stelara (ustekinumab).

Miraca Life Sciences continues to perform therapeutic drug monitoring (TDM) for Remicade® (infliximab), Humira® (adalimumab), Cimzia® (Certolizumab pegol) and Entyvio® (vedolizumab). Since […]

Continue reading


August 10, 2016

Ten Research Projects from Miraca Life Sciences Accepted for ACG Conference

IRVING, Texas, August 10, 2016 — Ten research projects from the GI pathologists at Miraca Life Sciences, the nation’s largest independent anatomic pathology lab, have been accepted for presentation at the Annual Meeting of the American College of Gastroenterology (ACG), which will be held October 14–19 in Las Vegas.

Authors from Miraca Life Sciences are linked below to their profile […]

Continue reading